Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating nipocalimab, a drug given intravenously or subcutaneously, for adults with generalized myasthenia gravis gMG, a condition causing muscle weakness. This Phase 3 study aims to compare the effectiveness and safety of nipocalimab against a placebo and to understand how the drug works in the body when given by injection under the skin versus through a vein. The study includes a subcutaneous substudy to explore these differences in delivery methods. Participants receive nipocalimab intravenous infusions every two weeks for up to 24 weeks during a double-blind placebo-controlled phase. Those completing this phase can enter an open-label extension, choosing to continue receiving intravenous nipocalimab or switch to the subcutaneous form given weekly for eight weeks, with the option to continue longer in a long-term extension. Placebo is also given intravenously every two weeks in the control group during the double-blind phase. Throughout the study, participants undergo regular assessments including muscle function scores, quality of life evaluations, and blood tests measuring antibody levels and drug concentration. Researchers monitor safety by tracking adverse events and changes in clinical and laboratory parameters. The study measures changes in activities of daily living related to myasthenia gravis over time. Participation may last several years, as long-term monitoring continues after the initial treatment phases to evaluate ongoing effects and safety.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of various drug regimens for people with myasthenia gravis, a condition that affects muscle strength. This platform study uses a master protocol allowing multiple treatments to be tested separately but under a common framework. The goal is to find treatments that reduce side effects and improve quality of life. Participants may receive treatments including intravenous infusions of efgartigimod, empasiprubart, or placebo, as well as subcutaneous injections of efgartigimod PH20 using a pre-filled syringe. The study includes different treatment groups based on specific myasthenia gravis subtypes and prior responses to therapy. Each treatment period varies in length depending on the specific intervention appendix. Throughout the study, participants undergo screening, treatment, and follow-up periods lasting up to approximately seven years depending on the treatment group. Researchers will monitor safety and tolerability as the primary outcomes, along with evaluating how well the treatments work. Participants will have regular assessments and safety monitoring throughout their involvement in the platform study.
Actively Recruiting
Researchers are evaluating the safety and therapeutic relevance of empasiprubart as an add-on treatment to efgartigimod in people with acetylcholine receptor antibody AChR-Ab seropositive generalized myasthenia gravis who have only partially responded to efgartigimod. This Phase 2a exploratory study is part of the larger ADAPT Forward platform, aiming to find safer and more effective treatment approaches to reduce side effects and improve quality of life for patients with myasthenia gravis. Participants first enter a run-in period where they receive intravenous efgartigimod. Those eligible then move to the add-on period, receiving both efgartigimod and empasiprubart intravenously. Participants not eligible for the add-on phase continue with efgartigimod alone during the safety follow-up period. The entire study duration for each participant lasts up to about 54 weeks. Throughout the study, participants are closely monitored with assessments including adverse event tracking, muscle strength and function evaluations, and quality of life questionnaires. The primary outcome is the incidence of adverse events during the first 21 weeks, with secondary measures examining changes in clinical scores such as MG-ADL and QMG. Safety follow-up continues for those not in the add-on phase to ensure ongoing monitoring of treatment effects.
Actively Recruiting
Researchers are investigating the safety and effectiveness of empasiprubart intravenous monotherapy in adults with acetylcholine receptor antibody AChR-Ab seropositive generalized myasthenia gravis gMG. This study is part of the broader ADAPT Forward platform, which aims to identify the best treatments that reduce side effects and improve quality of life for people with myasthenia gravis. The research is conducted under a phase 2a randomized, double-blinded, placebo-controlled trial design. Participants who qualify will be randomly assigned to receive either empasiprubart IV or a placebo during the double-blinded treatment period lasting up to 12 weeks. After this phase, all participants will receive open-label efgartigimod PH20 administered subcutaneously via pre-filled syringe during a safety follow-up period. The total study duration for each participant is approximately 45 weeks. Throughout the trial, participants will undergo various assessments including monitoring for adverse events, evaluation of myasthenia gravis activities of daily living MG-ADL scores, and quantitative myasthenia gravis QMG scores up to week 12. The study will track changes in these scores and the proportion of participants reaching meaningful clinical improvements. Safety and tolerability will be closely observed during treatment and follow-up periods to understand the effects of the study drugs.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of a new oral cladribine formulation in adults with Generalized Myasthenia Gravis gMG. This Phase 3 clinical trial compares two doses of cladribine with a placebo and also studies the long-term safety, sustained effects, and need for retreatment of cladribine in people with gMG. Additionally, the study will examine how the body processes cladribine through a pharmacokinetic sub-study. Participants are randomly assigned to one of three groups placebo, low dose cladribine, or high dose cladribine. Each group receives two separate treatment courses orally, starting on Day 1 and again at Week 5 during the double-blind placebo-controlled period. After this, participants enter a blinded extension where those initially on placebo switch to cladribine doses, and those initially on cladribine receive placebo courses. If needed, participants may enter a retreatment period to receive additional cladribine or placebo doses based on clinical judgment. During the study, participants undergo regular assessments including changes in muscle weakness and daily living activities using specific scales like the MG-ADL. Safety is monitored through tracking adverse events, lab tests, vital signs, and heart monitoring. The study also includes in-depth interviews with a subset of participants to understand their treatment and study experience. The total study duration extends up to 144 weeks, allowing long-term follow-up and evaluation.